Entera Bio Ltd. raises $275.0M (United States, Aug 2026)
$275.0M
$275MGenerated social card
Headline
ENTX: $275M financing in July 2026 secures funding for pivotal Phase 3 trial and extends cash runway to 2030 - TradingView
About
Entera Bio Ltd. is a biotechnology company focused on developing oral drug delivery systems for biologics. The company aims to improve patient compliance and expand the market for biologic therapies. The recent financing will support a pivotal Phase 3 trial for its lead product, EB613.
Article summary
ENTX: $275M financing in July 2026 secures funding for pivotal Phase 3 trial and extends cash runway to 2030 TradingView
Investors
Related rounds
| Aug 14, 2026 | MiiHealth AI | $2.8M | — | United States |
| Aug 14, 2026 | Alloy Robotics | $8.0M | Pre-seed | United States |
| Aug 14, 2026 | Zipline | $950.0M | Debt | United States |
| Aug 14, 2026 | InduPro | $77.0M | Series B | United States |